The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide vaccine in people aged 18 years and older. A randomized controlled, open trial design was adopted. The study was conducted with informed consent of the subjects for immunogenicity and safety in the population aged 18 years and older. A total of 3000 healthy subjects were selected, (1)600 healthy subjects were selected for the immunogenicity and safety study of co-immunization, 300 in the adult group (18-59 years old) and 300 in the elderly group (60 years old and above); (2) 2400 healthy subjects were selected for the observational study of the safety of co-immunization, 1200 in the adult group (18-59 years old) and 1200 in the elderly group (60 years old and above ) 1200 people.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
3,000
Different arms were administrated different vaccines
Daxing District Center of Disease Control and Prevention
Beijing, China
RECRUITINGHuairou District Center of Disease Control and Prevention
Beijing, China
RECRUITINGMiyun District Center of Disease Control and Prevention
Beijing, China
RECRUITINGSeroconversion rate of neutralizing antibody
Time frame: 28 days after the third dose of COVID-19 vaccine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.